News

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as ...
Fierce Pharma10h
GSK revs up launch plans after Nucala's FDA approval in COPD, targeting £500M opportunity
The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...
New Study Reveals The Shocking Reason Why Women Over 40 Are Getting COPD
A BMJ Open Respiratory Research study finds women aged over 40 face a 50% higher risk of developing COPD than men—even non-smokers. Indoor pollutants (cooking fumes, cleaning sprays), occupational ...
US Approves GSK’s Lung Disease Drug, Fueling Rivalry With Sanofi
GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.
The American Journal of Managed Care11h
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Rethinking COPD diagnosis to improve accuracy and early detection
University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...
American Lung Association19h
American Lung Association and CHEST Celebrate 120 Years of Lung Health with New Research Grant
In celebration of its 120th anniversary, the American Lung Association is joining with the American College of Chest Physicians (CHEST) to announce the opening of applications for the CHEST/ALA ...